Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Aug 05, 2022 12:27pm
118 Views
Post# 34874441

RE:RE:RE:RE:RE:RE:RE:Well We Will Soon Know Won’t We

RE:RE:RE:RE:RE:RE:RE:Well We Will Soon Know Won’t WeAbout saying whatever I want, I always do that, beenthere. But I never want to say anything unless I've studied news reports, scientific papers, company filings and publications, and many other sources. Then I try to offer good and understandable information and considered opinion about that information, not the trash talk that you and others put on here.

The one variable that can't be studied with any accuracy is management competency. This thing started with a capital pool in 2006. Sixteen years later, Bioasis has still not made the news, despite the importance of getting drugs into the CNS and xB3's apparent success in doing that. 

I'll tell you one thing, beenthere, I take no responsibility for management's failures. I certainly have done my part. But I must always make statements that only if Bioasis makes good things happen, then Bioasis shareholders will benefit from that. With respect to investing, I would call that axiomatic.

I don't know if the current management is failing or not. The market thinks the management is failing, or has failed. But, of course, there is money to be made only when we act on our disagreement with the market. .If all investors agreed on a stock, the share price couldn't move.

jd
<< Previous
Bullboard Posts
Next >>